1087 Mission St.
About AtomwiseAtomwise uses artificial intelligence to help discover new medicines. Based in San Francisco and funded by Data Collective, DFJ, and Khosla Ventures, we created the first Deep Learning Neural Network for drug discovery and design.
Founder and COO: Alexander Levy
CEO: Abraham Heifets
CTO: Izhar Wallach
Please click here for Atomwise job opportunitites.
Tweets by Atomwise
9 articles with Atomwise
AstraZeneca announced a long-term collaboration deal with BenevolentAI, a UK-based company focused on combining computational medicine and advanced artificial intelligence.This deal only marks one of the most recent AI team-ups announced in the biopharma industry.
Pharma and biotechs from across the globe share news, pipeline updates, with stories from Vetter, Atomwise, Tessa, GenSight, and more.
It’s not exactly breaking news that biopharma companies are increasingly turning toward machine learning and artificial intelligence (AI) to improve drug development. What is big news is how resoundingly it might improve on traditional methods.
As 2019 gets underway for the biopharma industry, more companies are increasing their reliance on the use of artificial intelligence as part of their drug discovery process.
Pfizer announced results from its Phase IIa clinical trial of PF-06651600 and PF-06700841 in alopecia areata (AA).
Atomwise, Inc., a leader in using artificial intelligence (AI) for drug screening and design, is now accepting applications for their 2018 Artificial Intelligence Molecular Screen (AIMS) awards. The awards support academic researchers in a wide variety of fields, from human and animal health to c...
Atomwise Raises $45 Million Series A to Become the Preferred Artificial Intelligence Partner for the Global Pharmaceutical Industry
The oversubscribed round brings Atomwise’s total capital raised to more than $51 million.
Monsanto And Atomwise Collaborate To Discover New Crop Protection Options Using Artificial Intelligence Technology